menu
    • menu
    [{"orgOrder":0,"company":"Acorda Therapeutics","sponsor":"Asieris Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Licensing Agreement","leadProduct":"Nepicastat","moa":"enzyme inhibitors: dopamine beta-hydrolase (DBH) inhibitors","graph1":"Neurology","graph2":"Preclinical","graph3":"Acorda Therapeutics","amount2":0.01,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0.01,"dosageForm":"Undisclosed","sponsorNew":"Acorda Therapeutics \/ Asieris Pharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"Acorda Therapeutics \/ Asieris Pharmaceuticals"}]

    Find Clinical Drug Pipeline Developments & Deals for Nepicastat

    Menu

    Nepicastat

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Acorda Therapeutics

                            U.S.A arrow
                            AAPS
                            Not Confirmed

                            Acorda Therapeutics

                            U.S.A arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Nepicastat

                            Therapeutic Area : Neurology

                            Study Phase : Preclinical

                            Sponsor : Asieris Pharmaceuticals

                            Deal Size : $7.5 million

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Acorda Therapeutics Enters into License Agreement with Asieris Pharmaceuticals

                            Details : SYN117 (nepicastat), is a small molecule drug and the license agreement provides for its development for all non-psychiatric indications and therapeutic uses. The asset has been held by Acorda’s U.S. subsidiary, Biotie Therapies, Inc.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : $0.5 million

                            August 29, 2022

                            Lead Product(s) : Nepicastat

                            Therapeutic Area : Neurology

                            Highest Development Status : Preclinical

                            Sponsor : Asieris Pharmaceuticals

                            Deal Size : $7.5 million

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth